View Post

FDA approves cancer treatment tested by Penn researchers

In In The News by Barbara Jacoby

By: John Kopp From: phillyvoice.com Azedra fights rare adrenal gland cancers through radiation Patients with adrenal gland cancers soon will have a new treatment option in their battle against the rare and highly-lethal diseases. The U.S. Food and Drug Administration approved a radiation therapy drug that provides the first non-surgical treatment for the neuroendocrine cancers pheochromocytoma and paraganglioma. The new …

View Post

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer

In In The News by Barbara Jacoby

From: PR Newswire Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. This additional FDA approval …

View Post

First treatment approved for breast cancer with BRCA genetic mutation

In In The News by Barbara Jacoby

By: Laurie McGinley From: washingtonpost.com The Food and Drug Administration on Friday cleared the first treatment for patients with advanced breast cancer caused by BRCA mutations, which are genetic defects that raise the risk of malignancies. The drug, called Lynparza, already is approved for certain patients with advanced ovarian cancer associated with the same mutations. Richard Pazdur, director of the …

View Post

Breakthrough Cancer Test Identifies Which of 15 Drugs Most Likely to Eradicate Tumors

In In The News by Barbara Jacoby

From: futurism.com In Brief The Food and Drug Administration has approved a “breakthrough device” that can match cancer patients with individualized treatment regiments with just one test. This device can detect 324 specific genetic mutations and two genomic signatures. Cancer Breakthrough The Food and Drug Administration (FDA) announced that it has approved a “breakthrough device” that has the potential to …

View Post

FDA approves one-of-a-kind cancer gene test

In In The News by Barbara Jacoby

By: Associated Press From: nypost.com U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what’s driving a patient’s tumor and aiding efforts to match treatments to those flaws. The U.S. Food and Drug Administration approved Foundation Medicine’s test for patients with advanced or widely spread …

View Post

Eli Lilly wins U.S. approval for breast cancer drug

In In The News by Barbara Jacoby

By: Bill Berkrot From: reuters.com The U.S. Food and Drug Administration said on Thursday it approved an Eli Lilly and Co drug to treat advanced breast cancer that has progressed following prior treatment. The drug, abemaciclib, which will be sold under the brand name Verzenio, will carry a list price before any discounts or rebates of about $10,948 per month, …

View Post

FDA approves new treatment to reduce the risk of breast cancer returning

In In The News by Barbara Jacoby

Source: U.S. Food and Drug Administration From: PR Newswire The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of …

View Post

FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency

In In The News by Barbara Jacoby

Source: The Lustgarten Foundation for Pancreatic Cancer Research From: PR Newswire In an unprecedented, fast-tracked review, the Food and Drug Administration (FDA) approved the use of pembrolizumab (anti-PDI) immunotherapy for patients with advanced pancreatic cancers who have a defect in their capacity to repair DNA.  Support from the Lustgarten Foundation was critical to the success of the clinical trial that …

View Post

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

In In The News by Barbara Jacoby

From: PR Newswire — Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack — Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay — Approval comes less than two months after Kisqali received US FDA approval  Novartis announced today that the US Food and Drug Administration (FDA) has approved the …

View Post

New surgical option for breast cancer comes to the US

In In The News by Barbara Jacoby

From: medicalxpress.com Breast cancer patients in the U.S. will have a new surgical option that eliminates exposure to radioactive materials and offers a less invasive, more flexible alternative for cancer detection. Receiving FDA approval in April and a distribution deal this month, the new device will be used to locate early stage tumors that cannot yet be felt. Co-invented by …